CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC

被引：10

作者：

Antonia, Scott J. ^{[1
]}

Gettinger, Scott N. ^{[2
]}

Goldman, Jonathan ^{[3
]}

Brahmer, Julie ^{[4
]}

Borghaei, Hossein ^{[5
]}

Chow, Laura Q. ^{[6
]}

Ready, Neal E. ^{[7
]}

Gerber, David E. ^{[8
]}

Juergens, Rosalyn ^{[9
]}

Shepherd, Frances ^{[10
]}

Laurie, Scott A. ^{[11
]}

Young, Tina ^{[12
]}

Geese, William J. ^{[12
]}

Agrawal, Shruti ^{[12
]}

Li, Xuemei ^{[12
]}

Hellmann, Matthew D. ^{[13
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Yale Comprehens Canc Ctr, New Haven, CT USA

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA

[4] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[6] Univ Washington, Seattle, WA 98195 USA

[7] Duke Univ, Med Ctr, Durham, NC USA

[8] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[9] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada

[10] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

[11] Univ Ottawa, Ctr Canc, Ottawa Hosp, Ottawa, ON, Canada

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 11期

关键词：

D O I：

10.1016/j.jtho.2016.09.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL01.03

引用

页码：S250 / S251

页数：3

共 50 条

[1] CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC
Hellmann, Matthew David
Gettinger, Scott N.
Goldman, Jonathan Wade
Brahmer, Julie R.
Borghaei, Hossein
Chow, Laura Q.
Ready, Neal
Gerber, David E.
Juergens, Rosalyn A.
Shepherd, Frances A.
Laurie, Scott Andrew
Zhou, Ye
Geese, William J.
Agrawal, Shruti
Li, Xuemei
Antonia, Scott Joseph
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012
Gettinger, Scott
Rizvi, Naiyer
Chow, Laura
Borghaei, Hossein
Brahmer, Julie
Shepherd, Frances
Ready, Neal
Gerber, David
Antonia, Scott
Goldman, Jonathan W.
Juergens, Rosalyn
Geese, William
Young, Tina
L, Xuemei, I
Hellmann, Matthew
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S250 - S251
[3] First-line nivolumab plus ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
O'Byrne, K. J.
Lee, K. H.
Kim, S-W
Park, K.
Nishio, M.
Sakai, H.
Ohe, Y.
Fukuhara, T.
Kang, J-H
Daga, H.
Yu, C-J
Hotta, K.
Tanaka, H.
Takeda, M.
Yokoyama, T.
Nathan, F. E.
Lee, J-S
[J]. ESMO OPEN, 2022, 7 (01)
[4] Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Paz-Ares, Luis G.
Ciuleanu, Tudor-Eliade
Pluzanski, Adam
Lee, Jong-Seok
Gainor, Justin F.
Otterson, Gregory A.
Audigier-Valette, Clarisse
Ready, Neal
Schenker, Michael
Linardou, Helena
Caro, Reyes Bernabe
Provencio, Mariano
Zurawski, Bogdan
Lee, Ki Hyeong
Kim, Sang-We
Caserta, Claudia
Ramalingam, Suresh S.
Spigel, David R.
Brahmer, Julie R.
Reck, Martin
O'Byrne, Kenneth J.
Girard, Nicolas
Popat, Sanjay
Peters, Solange
Memaj, Arteid
Nathan, Faith
Aanur, Nivedita
Borghaei, Hossein
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 79 - 92
[5] Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
Antonia, S.
Gettinger, S.
Borghaei, H.
Goldman, J. W.
Brahmer, J.
Ready, N.
Gerber, D.
Chow, L.
Juergens, R.
Laurie, S.
Shepherd, F.
Li, X.
Li, A.
Geese, W.
Hellmann, M.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S458 - S458
[6] CheckMate 817: First-Line Nivolumab plus Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC
Barlesi, F.
Audigier-Valette, C.
Felip, E.
Ciuleanu, T.
Jao, K.
Rijavec, E.
Urban, L.
Aucoin, J.
Zannori, C.
Vermaelen, K.
Frontera, O. A.
Ready, N.
Fontecedro, A. Curioni
Linardou, H.
Poddubskaya, E.
Fischer, J.
Iordan, I.
Groen, H.
Pillai, R.
Li, S.
Fiore, J.
Chang, H.
Acevedo, A.
Paz-Ares, L.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S214 - S215
[7] Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817
Barlesi, F.
Audigier-Valette, C.
Felip, E.
Ciuleanu, T-E.
Jao, K.
Rijavec, E.
Urban, L.
Aucoin, J-S.
Zannori, C.
Vermaelen, K.
Aren Frontera, O.
Ready, N.
Curioni, A.
Linardou, H.
Poddubskaya, E.
Fischer, J. R.
Pillai, R.
Li, S.
Acevedo, A.
Paz-Ares, L.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 33 - +
[8] Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
Brahmer, J. R.
Ciuleanu, T-E.
Schenker, M.
Audigier-Valette, C.
Zurawski, B.
Linardou, H.
Kim, S-W.
Otterson, G. A.
Salman, P.
De La Mora Jimenez, E.
Lesniewski-Kmak, K.
Ahmed, S.
Albert, I.
Barlesi, F.
Feeney, K.
Frickhofen, N.
Li, A.
Sun, P.
Hellmann, M.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1445
[9] First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update
Juergens, R.
Hellmann, M.
Brahmer, J.
Borghaei, H.
Gettinger, S.
Chow, L.
Gerber, D.
Laurie, S.
Goldman, J.
Shepherd, F.
Geese, W.
Young, T.
Li, X.
Antonia, S.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1792 - S1793
[10] CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC
Paz-Ares, L.
Urban, L.
Audigier-Valette, C.
Grossi, F.
Jao, K.
Aucoin, J.
Linardou, H.
Poddubskaya, E. Vladimirovna
Fischer, J.
Fontecedro, A. Curioni
Groen, H.
Vermaelen, K.
Bourhaba, M.
Kowalski, D.
Pillai, R.
Spigel, D.
Ahmed, S.
Hu, W.
Vickery, D.
Fiore, J.
Ready, N.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S493 - S493

← 1 2 3 4 5 →